Omnicare Company Profile (NYSE:OCR)

Analyst Ratings

Consensus Ratings for Omnicare (NYSE:OCR) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $98.00 (0.10% upside)

Analysts' Ratings History for Omnicare (NYSE:OCR)
Show:
DateFirmActionRatingPrice TargetActions
7/24/2015JPMorgan Chase & Co.DowngradeOverweight -> Neutral$90.00 -> $98.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2015Goldman Sachs Group Inc.DowngradeBuy -> Neutral$32.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015Cowen and CompanyDowngradeOutperform -> Market Perform$91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2015KeyCorpDowngradeOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2015Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$82.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2015Credit Suisse Group AGReiterated RatingOutperform -> Neutral$85.00 -> $91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2015Barclays PLCUpgradeEqual Weight -> Overweight$67.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Omnicare (NYSE:OCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/22/2015        
7/24/2015Q215$1.02$1.02$1.68 billion$1.70 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q1$1.01$1.02$1.64 billion$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414$0.95$0.96$1.61 billion$1.63 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2014Q314$0.92$0.94$1.60 billion$1.60 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214$0.90$0.91$1.59 billion$1.60 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2014Q114$0.90$0.91$1.55 billion$1.57 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413$0.90$0.87$1.59 billion$1.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2013Q313$0.90$0.91$1.55 billion$1.58 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2013Q2 2013$0.87$0.90$1.54 billion$1.57 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q1 2013$0.85$0.90$1.54 billion$1.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2013Q4 2012$0.85$0.86$1.51 billion$1.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2012Q312$0.80$0.86$1.54 billion$1.50 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2012$0.68$0.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.68$0.81ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2012$0.57$0.58ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2011$0.53$0.54ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011$0.50$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011$0.51$0.46ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Omnicare (NYSE:OCR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Current Dividend Information for Omnicare (NYSE:OCR)
Annual Dividend:$0.88
Dividend Yield:0.90%
Payout Ratio:21.20% (Based on Current Year Consensus EPS Estimate)
19.13% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:1.60% (3 Year Average)

Dividend History for Omnicare (NYSE:OCR)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
5/26/2015quarterly$0.220.92%6/10/20156/12/20156/30/2015Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015quarterly$0.221.14%3/10/20153/12/20153/27/2015Tweet This Announcement  Share This Announcement on StockTwits
12/5/2014quarterly$0.221.24%12/12/201412/16/201412/26/2014Tweet This Announcement  Share This Announcement on StockTwits
9/12/2014quarterly$0.201.27%9/18/20149/22/20149/29/2014Tweet This Announcement  Share This Announcement on StockTwits
5/27/2014quarterly$0.201.26%6/10/20146/12/20146/26/2014Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014quarterly$0.201.34%3/10/20143/12/20143/27/2014Tweet This Announcement  Share This Announcement on StockTwits
12/5/2013quarterly$0.201.36%12/12/201312/16/201312/24/2013Tweet This Announcement  Share This Announcement on StockTwits
12/5/2013$0.2012/12/201312/16/201312/24/2013Tweet This Announcement  Share This Announcement on StockTwits
9/12/2013quarterly$0.141.01%9/19/20139/23/20139/27/2013Tweet This Announcement  Share This Announcement on StockTwits
5/29/2013quarterly$0.141.2%5/30/20136/3/20136/14/2013Tweet This Announcement  Share This Announcement on StockTwits
2/19/2013quarterly$0.141.42%3/5/20133/7/20133/22/2013Tweet This Announcement  Share This Announcement on StockTwits
12/17/2012quarterly$0.141.56%12/20/201212/24/201212/28/2012Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Omnicare (NYSE:OCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/5/2015Steven J HeyerDirectorBuy6,630$75.46$500,299.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Amy WallmanDirectorSell5,672$63.84$362,100.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Robert KraftCFOBuy1,500$60.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Nitin SahneyCOOBuy10,000$58.49$584,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Randall A CarpenterSVPSell17,587$45.85$806,363.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Omnicare (NYSE:OCR)
DateHeadline
07/01/16 01:11 PMCVS Offers a Superb Bet on the Drug and Health Care Spending Boom -
05/13/16 04:21 PMStock Earnings Analysis: Ventas (VTR) - News Oracle - Stock Earnings Analysis: Ventas (VTR)News OracleHe formerly served as non-executive Chairman of the Board of Omnicare, Inc. (formerly NYSE: OCR) until it was attained by CVS Health Corporation in August 2015. Mr. Shelton also served as Chief Executive Officer and Chairman of the Board of Triad ...and more »
05/11/16 04:29 PMVentas, Inc. (NYSE:VTR) & UBS Group AG (USA) (NYSE:UBS) Financial Notable Runners - Wall Street 24 - Ventas, Inc. (NYSE:VTR) & UBS Group AG (USA) (NYSE:UBS) Financial Notable RunnersWall Street 24He formerly served as non-executive Chairman of the Board of Omnicare, Inc. (formerly NYSE: OCR) until it was attained by CVS Health Corporation in August 2015. Mr. Shelton also served as Chief Executive Officer and Chairman of the Board of Triad ...and more »
05/11/16 02:36 AMVentas Board Appoints James D. Shelton as Presiding Director - Business Wire (press release) - Ventas Board Appoints James D. Shelton as Presiding DirectorBusiness Wire (press release)Mr. Shelton is also a director of Envision (NYSE: EVHC), a healthcare services company. He previously served as non-executive Chairman of the Board of Omnicare, Inc. (formerly NYSE: OCR) until it was acquired by CVS Health Corporation in August 2015.and more »
05/05/16 09:36 AMCVS Earnings Review : Revenues, EPS Increase - CVS announced its Q1 earnings on Tuesday, May 3rd. The company’s revenue grew by 18.9% year-on-year (y-o-y) to $43.2 billion for the quarter. The rise in revenue was primarily driven by the strong performance of the PBM business and Retail/LTC business. The company’s operating profits increased by 2% year over year (y-o-y) to $2.2 billion. The figures were dented by the inclusion of the acquisition costs of Omnicare and Target Pharmacy. Excluding these costs, operating profit increased 5% y-o-y. The company’s adjusted earnings increased 4% over the prior year quarter to $1.18 per share, which were marginally better than market estimates of $1.16. The company also opened 24 new stores during the quarter, which took its store count to 9,674 at the end of Q1 2016. Buoyed by the increase in earnings, CVS increased its EPS guidance for full year 2016 from $5.73 to $5.88.
05/03/16 01:34 PMCVS Health Q1'16 Earnings Conference Call: Full Transcript - Operator: Ladies and gentlemen, thank you for standing by. Welcome to the CVS Health Q1 Earnings Call. During the presentation, all participants will be in a listen-only mode. Afterwards we will conduct a question and answer session. At that time if you have a question please press the one followed by the four on your telephone. If anytime during the conference you need to reach an operator, please press the star followed by the zero. As a reminder the call is being recorded, Tuesday May 3, 2016. And I would now like to turn the call over to Nancy Christal, Senior Vice President of Investor Relations.   Nancy R. Christal:Senior Vice President, Investor Relations, CVS Health: Thank you, James. Good morning, everyone and thanks for joining us. I’m here this morning with Larry Merlo, President and CEO; and Dave Denton, Executive Vice President and CFO. Jon Roberts, President of CVS Caremark and Helena Foulkes, President of CVS Pharmacy, are also with us today and will participate in the question and answer session following our prepared remarks. During the Q&A, please limit yourself to no more than one question with a quick follow-up so we can provide more people with the chance to ask their questions. Please note we posted a slide presentation on our website before the call. It summarizes the information in our prepared remarks as well as some additional facts and figures regarding our operating performance and guidance. Later this afternoon, we’d be filing our form 10-Q and it will also be available on our website at that time. In addition, note that during today’s presentation, we will make forward-looking statements within the meaning of the Federal Securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings including the Risk Factors section and Cautionary Statement disclosures in those filings. During this call we will use some non-GAAP financial measures when talking about our company’s performance; including free cash flow and adjusted EPS. In accordance with SEC regulations, you can find the reconciliation of these non-GAAP items to comparable GAAP measures on the Investor Relations portion of our website. And as always, today’s call is being simulcast on our website and it will be archived there following the call for one year. And now I’ll turn this over to Larry Merlo.   Larry J. Merlo:President and Chief Executive Officer, CVS Health: Well, thanks Nancy. Good morning everyone and thanks for joining us to hear about the solid first quarter results we posted today. Adjusted earnings per share increased 4% to $1.18 that’s $0.01 above the high end of our guidance. In total company revenues increased a very healthy 19% also above our high end guidance number. Excluding acquisition-related integration costs and the true-up of a legal charge, operating profit increased 5% enterprise wide with operating profit in the retail long-term care segment inline with our expectations and operating profit in the PBM notably exceeding expectations. We generated $1.8 billion of free cash during the quarterly and continued to return significant value to our shareholders through both dividends and share repurchases. Now its still early in the year so we are maintaining our adjusted EPS guidance range that we provided to you at our December Analyst Day and Dave will get into the details of our results and guidance in his remarks. So let me turn to the business update and I will start with the PBM selling season. Since our last update, the expected revenue impact for 2016 has grown with gross new business at $15.2 billion, net new business of $13.1 billion, both up above $400 million from our last update and the vast majority of these increase relates to a new health plan client which will increase our revenues in both 2016 and ‘17. We also closed out the ‘16 selling season with the retention rate of 97.3%. Now turning to the 2017 selling season, it’s early but we are off to a very good start. To date we have completed just over a third of our client renewals which is pretty typical for this time of the year. As for new business, our integrated model continues to resonate strongly and we have already had some nice wins. Prospective clients value our strong service and execution, competitive pricing, unmatched products and services along with our ability to meet their unique needs. Now many of you have asked about the magnitude of the ‘17 selling season and at this point we are seeing more RFPs and potential revenues in the marketplace than we did at the same time last year. But keep in mind that it ebbs and flows throughout the season and some of that could simply be timing. Now given that it’s still early and consistent with our past practices, we will provide a quantitative update on our next earnings call once we have a more complete picture of the selling season. Now we held our client forum in late March which was attended by about 900 people and clients acknowledge that their top concern is cost management with service running at close second. And I am pleased to report that we have been able to deliver on both fronts. In this environment of rising healthcare costs, clients are looking to us for proactive cost management solutions that anticipate market changes that impact trend. And they are adopting more aggressive strategies particularly formulary design and specialty management communicate to mitigate these trend drivers. Now we believe we are offering our clients the most comprehensive suite of formulary choices to achieve their savings goals while addressing member impacts and transition to new therapies. In addition specialty drug management has been emphasized in the plan design elections and clients are looking for solutions for managing specialty in both the pharmacy and the medical benefits. Among our unique specialty management programs we are seeing a growing interest in our infusion and site of care services as well as our medical claims management services. In addition, innovations in specialty include indication-specific pricing where the cost to the payer is aligned with a drug’s effectiveness for a specific indication. In the first quarter, specialty revenues increased 23% and our volumes continued to outpace the market. So through our unique suite of specialty capabilities, we remain highly focused on helping our clients manage cost and improve outcomes. Now let me turn to the retail long-term care segment and I will start with an update on the integrations of the Target and Omnicare. The integration of the acquired Target Pharmacies and Clinics is proceeding according to plan and as of the end of April, about half of the 1,670 acquired pharmacies have been successfully converted to the CVS Pharmacy brand and systems. As planned we expect that all store conversions will be completed by the end of this summer and as the stores are converted and rebranded, we are launching our additional core pharmacy offerings and these include Specialty Connect, ExtraCare Pharmacy Rewards and our digital tools, and this is in addition to Maintenance Choice which is been available since the transaction closed. So we are pleased with our early progress and remain very enthusiastic about this opportunity to drive growth. Turning to Omnicare, the long-term care pharmacy business performed in line with our expectations as we benefited from some of the anticipated cost and sourcing synergies. Currently, we are working to combine operational infrastructures and further develop programs to improve work streams and enhanced service delivery and we are on track to complete the vast majority of the Omnicare integration activities by year-end. Now in addition to the integration work we have several initiatives underway. We have piloted and have already rolled out the use of CVS Pharmacies as an extension of the Omnicare Pharmacies to speed the delivery of first pills or emergency order prescription in the skilled nursing facilities. We are also currently piloting an integrated service offering to the assistant and independent living communities where we can offer residents enhanced medication delivery options based on their preference and acuity level, all supported by our high touch patient care teams. And with a targeted marketing approach that focused on when people enter these facilities along with our name brand recognition, we are confident that we can increase our penetration in these segments. In pending the pilot resolve this program will begin to roll out later this year. So with the combination of CVS and Omnicare, we remain very excited about our enhanced ability to serve seniors along their continuum of care. Now moving on to first quarter results in the retail business; total same-store sales increased 4.2% and were positively affected approximately 125 basis points due to the additional day related to leap year. Pharmacy same-store sales increased 5.5%. This was negatively impacted by approximately 360 basis points due to recent generic introductions and about 50 basis points related to the softer flu season and the flu was pretty soft in the first two months in the quarter but strong in March somewhat mitigating the quarterly impact. Pharmacy comps were positively impacted by about 130 basis points related to the extra leap day and pharmacy same-store prescription volumes increased 5.9% on a 30-day equivalent basis continuing to outperform overall market growth. And our retail pharmacy market share on a 30-day equivalent basis with 23.9% in Q1 and that’s up about 245 basis points versus the same quarter a year ago. And while the primary driver of share growth is the addition of the Target Pharmacies, we continued to experience strong organic share growth as well. Now an important driver of script growth has been our clinical outreach programs which have allowed us to continue to improve adherence and provide patients helpful reminders. Part of the strength of these programs has been the integration of our digital tools and today nearly 90 million people receive text alerts from CVS on a variety of topics, all of which help to enhanced the service experience. Among other recent pharmacy innovations, ScriptSync retail is expected to continue to improve medication adherence and patient satisfaction. Since the launch, more than two-thirds of the patients offered ScriptSync have adopted the service and with nearly 350,000 patients enrolled in ScriptSync during the first quarter, we now have more than 1 million patients enrolled since its launch in the third quarter of last year. In the front store business, comps increased 0.7% and this includes the benefit of the extra day from leap year of approximately 105 basis points as well as the shift of the Easter holiday from April last year to March this year positively impacting front store comps by about 80 basis points. And the negative impact of a late flu season was immaterial to the front store in the quarter. Now, we’ve continued to pull back on broad based promotions which has resulted in fewer business from lower value customers. Front store margins once again increased notably in the quarter, benefiting from these efforts to rationalize our promotional strategies along with growth in the higher margin health and beauty businesses. So, we continue to test, learn, and refine strategies to achieve the optimal balance between traffic and profitable growth. Now ExtraCare continues to reward our loyal customers with savings and we continue to leverage our ExtraCare data to create even more relevant and personalized communications, and we know that our top customers drive the at disproportionate amount of our sales and margins so while store traffic overall is down, our loyal customers are shopping frequently and driving our front store sales and margins. As for store brands they represented 21.9% of front store sales in the quarter. That’s up 100 basis points from the same quarter last year and there remain significant opportunities to expand our share of store brand products by building our core equities in health and beauty and seeking opportunistic growth in other areas where we can provide customers a superior value. Among our recent front store innovations, we recently announced the partnership with Curbside to bring a new level of convenience to our customers. CVS Express is the industry’s first retail solution that integrates Curbside’s market leading technology right into the CVS pharmacy app. Customers can make mobile in-app purchases from their local CVS Pharmacy and have the products directly delivered to them when they pull up to the store -- about an hour with no added costs. This service is currently available in select markets including San Francisco, Charlotte and Atlanta pending a successful pilot, our goal is to roll out the program to the majority of our markets later this year and this exciting new initiative really embodies the digital mission of CVS Health to make healthy lifestyles more accessible and convenient for our customers all across the country. Now turning to store openings. In the first quarter we opened 24 new stores, relocated 14 others, closed five, resulting in 19 net new stores and we expect to open about 100 net new stores for the full year. As for MinuteClinic, the Target integration was completed in 24 clinics converting them to MinuteClinic’s branding, electronic health record systems and health offerings and we expect the balance of the clinics to be converted by the end of the summer. We now operate 1,136 clinics across 33 states plus the District of Columbia and including Target MinuteClinic’s revenues increased 17.7% versus the same quarter last year despite the mild and late flu season. Another digital innovation is what we call the hold my place in line online queuing tool that was launched nationally at MinuteClinic in late March and this tool enhances convenience by allowing patients the view wait times online and hold their place in line through any digital channel. So MinuteClinic continues to advance in innovative ways to increase convenience in access to cure. So with that let me turn over it to Dave for the financial review.   David M. Denton:Executive Vice President and Chief Financial Officer, CVS Health: Thank you Larry and good morning everyone. This morning I will provide a detail review of our first quarter results followed briefly with an update on our guidance. And as always I will start first with the summary of the various ways we continue to enhance shareholder value through our capital allocation program. Throughout the quarter, our quarterly cash dividend increased by 21% per share and we paid approximately $470 million in dividends. Our dividend payout ratio currently stands at 31.9% and we’ve remained well on track to achieve our target of 35% by 2018. In addition, we have continued to repurchase our shares. In the first quarter we repurchased approximately 22.4 million shares for $2.1 billion for approximately $98.52 per share. So between dividends and share repurchases, we’ve returned approximately $2.5 billion to our shareholders in the first quarter alone. Looking forward to remainder of the year, we continue to expect to repurchase an additional $1.8 billion worth of our stock completing the planned $4 billion in repurchases for the full year. Our expectation is that we will return more than $5 billion to our shareholders in 2016 through a combination of both dividends and share repurchases. As Larry mentioned, we generated approximately $1.8 billion of free cash in the first quarter and we continue to expect to produce cash of between $5.3 billion and $5.6 billion this year. Turning to the income statement. Adjusted earnings per share came in at $1.18 per share $0.01 above the top of our guidance range and 4% over LY. GAAP diluted EPS was $1.04 per share. The retail long term care segment delivered solid earnings within expectations while the PBM segment posted profit growth above the high end of our guidance. The outperformance in the quarter was primarily driven by stronger than expected volumes and better purchasing economics within the PBM. With that, let me quickly walk down the P&L. On a consolidated basis, revenues in the first quarter increased 18.9% to $43.2 billion. In the PBM segment, net revenues increased 20.5% to $28.8 billion. Given the large amount of new business that came on board on 1/1, this growth is attributable to the increased volume in pharmacy network claims as well as growth in specialty pharmacy. Overall PBM adjusted claims grew 19.4% in the quarter partially offsetting the sales growth was a 170 basis point increase in our generic dispensing rate to 85.2%. In our retail long term care business, revenues increased 18.6% in the quarter to $20.1 billion, driven primarily by the addition of Omnicare and the Target Pharmacies. Solid pharmacy same-store sales contributed as well. This revenue growth was just below our guidance range. While script unit growth remained strong, the mix of branded drugs deferred slightly from our plan resulting in a lower average script price. To be clear, we have not seen a change in the level of branded drug inflation. It was simply mix that effected the weighted average script price. In addition, front store revenues were impacted by our promotional strategies in our non-health and beauty categories as we gave up some lower value customer traffic to drive an increasingly profitable front store sales mix. GDR increased by approximately 125 basis points to 85.7%. Turning to gross margin, operating expenses, operating profit, and the tax rate. The numbers I’ll site exclude non-GAAP adjustments mainly amortization, acquisition related costs, and the legal charge where applicable. Keep in mind that our guidance for the quarter also excluded these items. We reported gross margin of 15.6% for the consolidated company in the quarter, a contraction of approximately 135 basis points compared to Q1 ‘15. Gross profit dollars increased a healthy 9.5%, in line with our expectations. Within the PPM segment, gross margins contracted by approximately 45 basis points versus Q1 of ‘15 to 3.8% primarily due to the mix of new business and price compression partially offset by the GDR improvement and favorable purchasing economics. However hHwever, gross profit dollars increased 7.4% year-over-year due in part to strong volumes, specialty pharmacy, the improvement in GDR, and again favorable purchasing economics. Partially offsetting these drivers was continued price compression. Gross profit dollars increased approximately 10% year-over-year in the retail long-term care segment while gross margin declined approximately 225 basis points to 29%. Now about 40% of the decline in the gross margin rate was mix driven due to the inclusion of the Omnicare and Target businesses that we acquired. The decline in gross margin was also due to continued reimbursement pressures. Gross margin was positively impacted by the increase in GDR as well as increased front store margins due to our continued rationalization of our promotional strategies and improved mix of the products that we sold. Turning to expenses, we saw strong improvement in total operating expenses as a percent of revenues from Q1 of ‘15 to 10.4%. The PBM segment SG&A rate improved about 10 basis points to 1.1% benefiting from additional sales leverage. SG&A as a percent of sales in the retail long-term care segment improved significantly by approximately 120 basis points to 19.9%. These too was driven by leverage from revenue growth as well as the addition of the Omnicare business which carries a lower SG&A relative to sales. Within the corporate segment, expenses were up approximately $20 million to $209 million slightly better than expectations. Operating margin for the total enterprise decreased approximately 70 basis points in the quarter to 5.2%. Operating margin in the PBM decreased approximately 35 basis points to 2.7% while operating margin at retail long-term care, decreased approximately 105 basis points to 9.1%. For the quarter, operating profit growth in each segment was in line with or better than expectations with the PBM increasing 6.6% and retail long term care growing 6.4%. Going below the line on the consolidated income statement, net interest expense in the quarter increased approximately $149 million from OI to $283 million. This was due primarily to the debt associated with the acquisitions that we took on last year. Our effective tax rate in the quarter was 39.3% and our weighted average share count was 1.1 billion shares. Now let me update you on our guidance. I’ll focus on the highlights and you can find the additional details of our guidance in the slide presentation that we posted on our website earlier this morning. As Larry said, we are confirming our 2016 adjusted earnings per share guidance range of $5.73 to $5.88 which reflects strong year-over-year growth of ...Full story available on Benzinga.com
04/28/16 04:37 PMHealth care services company plans $25 million expansion, 400 new jobs - Louisville Business First - Louisville Business FirstHealth care services company plans $25 million expansion, 400 new jobsLouisville Business FirstI contacted RxCrossroads officials for comment on the expansion but have not heard back. A Jefferson United official declined comment. RxCrossroads is a division of Cincinnati-based Omnicare Inc. (NYSE: OCR), a Fortune 500 company that provides ...and more »
04/28/16 12:05 PMHealth care services company plans $25 million expansion, 400 new jobs -
03/16/16 04:21 PMCOLONY GROUP Top 10 Holdings in Q3 2015 - OctaFinance.com - COLONY GROUP Top 10 Holdings in Q3 2015OctaFinance.comThis fund got rid of its stakes in Omnicare Inc (OCR), Tenn Co Xxx (ROCK), Micron Technology (MU), Ishares India 50 (INDY) and Trinet Group Inc (TNET). These securities constituted 1.88 %, 1.08 %, 0.45 %, 0.18 % and 0.15 % of the portfolio, respectively.
03/03/16 09:00 AMTransaction expected to be accretive to CVS Health's earnings and cash flow - WOONSOCKET, R.I. and CINCINNATI, May 21, 2015 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) and Omnicare, Inc. (NYSE: OCR) announced today that they have entered into a definitive agreement for CVS Health to acquire Omnicare, the leading provider of ...
03/01/16 03:35 PMNeed for Risk Management in Healthcare Will Expedite the Global Healthcare SCM Market Through 2020, says ... - Business Wire (press release) - Need for Risk Management in Healthcare Will Expedite the Global Healthcare SCM Market Through 2020, says ...Business Wire (press release)Drugstore operator CVS Health (CVS) is acquiring pharmacy services provider Omnicare (OCR) for USD 12.7 billion. “Competition in the healthcare sector is accelerating as many large hospitals acquire smaller hospitals. This should help large hospitals ...and more »
02/12/16 08:58 AMCVS Earnings: Strong Performance Driven by Acquisitions and Growth In Specialty Business - Leading U.S. pharmacy services provider in the , CVS Health reported its Q4 2015 earnings on February 9th. The company closed its fiscal 2015 on a strong note, driven by its acquisition of the pharmacy businesses within Target and Omnicare. Target’s pharmacy, spread throughout its retail chain, is a sizable addition to CVS’ core business. On the other hand, Omnicare is the leading pharmacy benefits manager serving the long-term care facility sector and augments its services business. For full year 2015, CVS revenue and diluted earnings per share increased by 10% and 17%, respectively, to $153 billion and $4.63. Backed by the recent acquisitions, the company is confident of accelerating its growth momentum in fiscal 2016 (guidance provided below)
02/09/16 08:56 AMNew Pharmacies And PBM Growth Boost CVS Health Profits - Forbes - ForbesNew Pharmacies And PBM Growth Boost CVS Health ProfitsForbesBuoyed by the addition of new employer clients for its pharmacy benefit management business, Target TGT +0.63% (TGT) pharmacies and the Omnicare specialty pharmacy business, CVS Health CVS -3.71% (CVS) said profits jumped 13 percent in the fourth ...CVS: Delivering Growth In Turbulent TimesSeeking AlphaCVS meets 4Q profit forecasts, reaffirms 2016 outlookU.S. News & World ReportCVS profit grows, but outlook softMarketWatchReutersall 111 news articles »
10/27/15 05:51 PMWalgreens Boots to buy Rite Aid in $17.2 bn deal -
10/21/15 07:00 AMTailwind Capital Expands its Healthcare Team - [Business Wire] - Tailwind Capital, a leading middle market private equity firm investing in growth-oriented companies in targeted sectors in healthcare, business and communications services, announced that it has recently added Eran Broshy and Cliff Gookin as Operating Executives.
10/14/15 04:14 PMOMNICARE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
10/09/15 11:17 AMCVS Health Corporation Announces Results to Date of Exchange Offers and Consent Solicitations - [at noodls] - WOONSOCKET, R.I., Oct. 6, 2015 /PRNewswire/ -- CVS Health Corporation ('CVS Health', NYSE: CVS) announced today the results to date for the previously announced (A) private exchange offers ('Exchange Offers') ...
09/15/15 04:19 PMOmnicare Trust PIERS to Accrue Contingent Interest - [at noodls] - CINCINNATI, September 15, 2015 - Omnicare, Inc. announced today that, for the quarterly interest period beginning September 15, 2015, its Trust Preferred Income Equity Redeemable Securities (NYSE: OCR.PRA ...
08/22/15 12:04 PMOMNICARE INC Financials -
08/18/15 05:02 PMOmnicare Announces Conversion Rate Adjustments for Convertible Notes - [at noodls] - CINCINNATI, August 18, 2015 - Omnicare, Inc. (the 'Company') announced today an adjustment to the conversion rate of its (i) 3.75% Convertible Senior Subordinated Notes due 2025 (the '2025 Notes'), (ii) ...
08/18/15 03:59 PMOMNICARE INC Files SEC form 8-K, Financial Statements and Exhibits -
08/18/15 09:52 AMCVS Health Completes Omnicare Acquisition - [at noodls] - WOONSOCKET, R.I., Aug. 18, 2015 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) announced today that it has completed the acquisition of Omnicare, the leading provider of pharmacy services to long term ...
08/12/15 04:39 PMCare Capital Properties Set to Join the S&P MidCap 400 - [PR Newswire] - NEW YORK, Aug. 12, 2015 /PRNewswire/ -- Care Capital Properties Inc. (NYSE:CCPwi) will replace Omnicare Inc. (NYSE:OCR) in the S&P MidCap 400 after the close of trading on Monday, August 17. S&P 500 constituent ...
08/12/15 07:02 AMOmnicare (OCR) is in Overbought Territory: What's Next? -
08/07/15 08:06 AMMcKesson Corp. Earnings Analysis: By the Numbers Q2*, 2015 -
08/06/15 04:26 PMOMNICARE INC Files SEC form 8-K, Other Events -
08/06/15 10:06 AMCVS Eyes Specialty Pharmacy Opportunity through Acquisitions -
08/05/15 05:23 PMMario Gabelli's Top 5 New Stock Buys of Q2 -
08/04/15 11:06 AMExpress Scripts Holding Co. Earnings Q2*, 2015 -
07/31/15 10:34 AMLALT: A True Hedge ETF -
07/29/15 04:29 PMOMNICARE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -

Social

About Omnicare

Omnicare logoOmnicare, Inc. is a healthcare services company that specializes in the management of complex pharmaceutical care. The Company operates two primary businesses, Long-Term Care Group (LTC) and Specialty Care Group (SCG), each serving different customer populations. Through LTC, the Company is a provider of pharmaceuticals and related pharmacy and ancillary services to long-term care facilities, as well as chronic care facilities and other settings. As of December 31, 2014, LTC provided pharmacy services in the United States in 47 states and the District of Columbia. The Specialty Care Group (SCG) operates across a spectrum of the healthcare continuum, serving the needs of biopharmaceutical manufacturers, physicians, nurses, caregivers and patients. Its SCG services are primarily focused on the specialty pharmaceutical market and incorporate four platforms: brand support services, supply chain solutions, patient support services and specialty pharmacy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialized Health Services
  • Sub-Industry: Health Care Services
  • Exchange: NYSE
  • Symbol: OCR
  • CUSIP: 68190410
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $96
  • 200 Day Moving Average: $87
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $4.15 EPS
  • Next Year EPS Consensus Estimate: $4.60 EPS
Additional Links:
Omnicare (NYSE:OCR) Chart for Saturday, July, 23, 2016